See where GLP, GCP, and GCLP apply in drug development & use our decision framework to select the right-fit compliance.
See how these designated workflows meet enhanced quality and traceability standards for assays used in clinical trials.
How this AI-based model reads dynamic patient physiology that determines disease trajectory, drug response & toxicity.
See how our metabolomics platform uncovered new biomarkers of cancer therapy-related cardiac dysfunction.
See the discoveries uncovered from this multi-omics study led by a large industry-academia collaboration.
Reframing targeted protein measurement from indirect antibody-based approaches to a direct, absolute readout of the key protein.
Covers innate & adaptive immunity, cytokines, chemokines, checkpoints, and cell-death pathways – in a single run.
How our MS-based platform defines a tumor's protein variants in tissue & detects them in blood with high sensitivity.
How next-gen mass spec FFPE proteomics enables retrospective discovery in archived tissue, unlocking new biomarkers & targets.
Learn how protein-level evidence can augment or replace genomic inference at critical drug development decision points.
Using discovery metabolomics to map fetal phenotypes underlying childhood developmental deficiencies.
Turning normal tissue biology from a late-discovered liability into an early part of target evaluation.
